Stonebrook Private Inc. Invests $706,000 in IQVIA Holdings Inc. (NYSE:IQV)

Stonebrook Private Inc. bought a new position in shares of IQVIA Holdings Inc. (NYSE:IQV) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 3,053 shares of the medical research company’s stock, valued at approximately $706,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. AdvisorNet Financial Inc lifted its stake in IQVIA by 327.6% in the 4th quarter. AdvisorNet Financial Inc now owns 124 shares of the medical research company’s stock valued at $29,000 after buying an additional 95 shares in the last quarter. BKM Wealth Management LLC purchased a new position in IQVIA in the 4th quarter valued at about $32,000. Activest Wealth Management purchased a new position in IQVIA in the 4th quarter valued at about $35,000. CVA Family Office LLC purchased a new position in IQVIA in the 4th quarter valued at about $43,000. Finally, CoreFirst Bank & Trust purchased a new position in IQVIA in the 3rd quarter valued at about $44,000. 89.62% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at IQVIA

In other IQVIA news, insider Eric Sherbet sold 1,000 shares of the firm’s stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $241.50, for a total value of $241,500.00. Following the completion of the transaction, the insider now owns 20,836 shares of the company’s stock, valued at approximately $5,031,894. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In related news, insider Kevin C. Knightly sold 8,607 shares of the business’s stock in a transaction on Wednesday, February 28th. The shares were sold at an average price of $250.17, for a total value of $2,153,213.19. Following the completion of the sale, the insider now directly owns 5,251 shares of the company’s stock, valued at $1,313,642.67. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Eric Sherbet sold 1,000 shares of the business’s stock in a transaction on Friday, February 16th. The shares were sold at an average price of $241.50, for a total transaction of $241,500.00. Following the completion of the sale, the insider now directly owns 20,836 shares of the company’s stock, valued at $5,031,894. The disclosure for this sale can be found here. Insiders sold 41,285 shares of company stock valued at $10,331,003 in the last 90 days. Company insiders own 1.60% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have commented on the stock. Robert W. Baird increased their price objective on shares of IQVIA from $226.00 to $251.00 and gave the company a “neutral” rating in a report on Thursday, February 15th. Leerink Partnrs reiterated an “outperform” rating on shares of IQVIA in a report on Monday, February 26th. StockNews.com upgraded shares of IQVIA from a “hold” rating to a “buy” rating in a report on Friday, February 16th. Truist Financial increased their price objective on shares of IQVIA from $286.00 to $297.00 and gave the company a “buy” rating in a report on Tuesday, February 27th. Finally, SVB Leerink assumed coverage on shares of IQVIA in a report on Monday, February 26th. They issued an “outperform” rating and a $290.00 price objective for the company. Three analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. According to MarketBeat.com, IQVIA currently has a consensus rating of “Moderate Buy” and an average target price of $256.80.

IQVIA Trading Up 0.4 %

IQVIA stock traded up $0.90 during trading on Friday, hitting $234.88. The company had a trading volume of 697,640 shares, compared to its average volume of 761,918. IQVIA Holdings Inc. has a 1-year low of $167.42 and a 1-year high of $261.73. The company has a current ratio of 0.86, a quick ratio of 0.86 and a debt-to-equity ratio of 2.12. The company’s 50 day simple moving average is $245.28 and its 200-day simple moving average is $223.17. The stock has a market cap of $42.63 billion, a price-to-earnings ratio of 32.22, a price-to-earnings-growth ratio of 2.27 and a beta of 1.50.

IQVIA (NYSE:IQV) last posted its earnings results on Wednesday, February 14th. The medical research company reported $2.84 earnings per share for the quarter, beating the consensus estimate of $2.82 by $0.02. IQVIA had a net margin of 9.06% and a return on equity of 29.32%. The firm had revenue of $3.87 billion during the quarter, compared to the consensus estimate of $3.80 billion. During the same quarter last year, the firm earned $2.54 EPS. The firm’s revenue for the quarter was up 3.5% on a year-over-year basis. As a group, analysts expect that IQVIA Holdings Inc. will post 10.12 EPS for the current fiscal year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.